Extremity Medical Enters into Strategic Relationship with Henry Schein, Inc. and Closes Growth Financings
December 2023 –England & Company is pleased to announce the closing of several strategic and financial transactions for Extremity Medical, LLC in 2023. Extremity Medical is an orthopedic medical device company specializing in extremity implants known for improved outcomes, especially in patients with poor bone quality. Based in Parsippany, NJ, Extremity Medical develops and markets proprietary, next-generation products to address fixation, fusion and motion preservation in procedures in the lower and upper extremities, including the foot & ankle, hand, and wrist. It is one of the largest privately held independent companies in the U.S. serving the foot & ankle market.
Extremity Medical has entered into a strategic relationship with Henry Schein, Inc. (NASDAQ: HSIC), a leading FORTUNE 500 global healthcare products and solutions company, and a new entrant into the orthopedic extremities market. The relationship is part of Henry Schein’s expansion in orthopedics and complementary to Schein’s pending acquisition of TriMed, Inc. For more information about Schein’s expansion, please see this link.
Matthew Lyons, Extremity’s Chairman and Chief Executive Officer, said, “We are very excited to be working with Henry Schein in its build up in orthopedic extremities. They will bring significant complementary products and sales channels with TriMed. It’s a perfect fit between Extremity’s full portfolio of innovative lower extremity products and wrist replacement and TriMed’s leading portfolio of upper extremity products.” Lyons added “The England team did a great job identifying this creative opportunity, leading the negotiations and bringing the transaction to the finish line.”
England also closed a total of $21 million in convertible note and working capital financings for Extremity Medical between June and November of this year. Extremity Medical will use the new capital provided by its latest financing to invest in the growth of its business and refinance existing debt. Lyons said “The England team was instrumental in securing us innovative growth and working capital financing solutions in a challenging environment.”
Extremity Medical’s innovative product portfolio includes advanced implant systems for addressing Charcot neuropathy in diabetic patients, as well as less-invasive surgical implants to correct common foot deformities, and address trauma and arthritis. Extremity Medical also offers a revolutionary total wrist replacement to restore more natural wrist motion in arthritic patients.
Extremity Medical Enters into Strategic Relationship with Henry Schein, Inc.
December 2023 –England & Company is pleased to announce the closing of several strategic and financial transactions for Extremity Medical, LLC in 2023. Extremity Medical is an orthopedic medical device company specializing in extremity implants known for improved outcomes, especially in patients with poor bone quality. Based in Parsippany, NJ, Extremity Medical develops and markets proprietary, next-generation products to address fixation, fusion and motion preservation in procedures in the lower and upper extremities, including the foot & ankle, hand, and wrist. It is one of the largest privately held independent companies in the U.S. serving the foot & ankle market.
Extremity Medical has entered into a strategic relationship with Henry Schein, Inc. (NASDAQ: HSIC), a leading FORTUNE 500 global healthcare products and solutions company, and a new entrant into the orthopedic extremities market. The relationship is part of Henry Schein’s expansion in orthopedics and complementary to Schein’s pending acquisition of TriMed, Inc. For more information about Schein’s expansion, please see this link.
Matthew Lyons, Extremity’s Chairman and Chief Executive Officer, said, “We are very excited to be working with Henry Schein in its build up in orthopedic extremities. They will bring significant complementary products and sales channels with TriMed. It’s a perfect fit between Extremity’s full portfolio of innovative lower extremity products and wrist replacement and TriMed’s leading portfolio of upper extremity products.” Lyons added “The England team did a great job identifying this creative opportunity, leading the negotiations and bringing the transaction to the finish line.”
England also closed a total of $21 million in convertible note and working capital financings for Extremity Medical between June and November of this year. Extremity Medical will use the new capital provided by its latest financing to invest in the growth of its business and refinance existing debt. Lyons said “The England team was instrumental in securing us innovative growth and working capital financing solutions in a challenging environment.”
Extremity Medical’s innovative product portfolio includes advanced implant systems for addressing Charcot neuropathy in diabetic patients, as well as less-invasive surgical implants to correct common foot deformities, and address trauma and arthritis. Extremity Medical also offers a revolutionary total wrist replacement to restore more natural wrist motion in arthritic patients.
Extremity Medical Enters Closes Growth Financings
December 2023 –England & Company is pleased to announce the closing of several strategic and financial transactions for Extremity Medical, LLC in 2023. Extremity Medical is an orthopedic medical device company specializing in extremity implants known for improved outcomes, especially in patients with poor bone quality. Based in Parsippany, NJ, Extremity Medical develops and markets proprietary, next-generation products to address fixation, fusion and motion preservation in procedures in the lower and upper extremities, including the foot & ankle, hand, and wrist. It is one of the largest privately held independent companies in the U.S. serving the foot & ankle market.
Extremity Medical has entered into a strategic relationship with Henry Schein, Inc. (NASDAQ: HSIC), a leading FORTUNE 500 global healthcare products and solutions company, and a new entrant into the orthopedic extremities market. The relationship is part of Henry Schein’s expansion in orthopedics and complementary to Schein’s pending acquisition of TriMed, Inc. For more information about Schein’s expansion, please see this link.
Matthew Lyons, Extremity’s Chairman and Chief Executive Officer, said, “We are very excited to be working with Henry Schein in its build up in orthopedic extremities. They will bring significant complementary products and sales channels with TriMed. It’s a perfect fit between Extremity’s full portfolio of innovative lower extremity products and wrist replacement and TriMed’s leading portfolio of upper extremity products.” Lyons added “The England team did a great job identifying this creative opportunity, leading the negotiations and bringing the transaction to the finish line.”
England also closed a total of $21 million in convertible note and working capital financings for Extremity Medical between June and November of this year. Extremity Medical will use the new capital provided by its latest financing to invest in the growth of its business and refinance existing debt. Lyons said “The England team was instrumental in securing us innovative growth and working capital financing solutions in a challenging environment.”
Extremity Medical’s innovative product portfolio includes advanced implant systems for addressing Charcot neuropathy in diabetic patients, as well as less-invasive surgical implants to correct common foot deformities, and address trauma and arthritis. Extremity Medical also offers a revolutionary total wrist replacement to restore more natural wrist motion in arthritic patients.